4779 related articles for article (PubMed ID: 6099419)
21. Oral (1-->3),(1-->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma.
Cheung NK; Modak S
Clin Cancer Res; 2002 May; 8(5):1217-23. PubMed ID: 12006541
[TBL] [Abstract][Full Text] [Related]
22. Production of anti-tumor human monoclonal antibodies using different approaches.
Liu H; Xu ZL; Wang Y; Yang L; Feng O; Li Y; Wang YM; Zhang GG
Hum Antibodies Hybridomas; 1993 Jan; 4(1):2-8. PubMed ID: 8381684
[TBL] [Abstract][Full Text] [Related]
23. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody.
Mueller BM; Romerdahl CA; Gillies SD; Reisfeld RA
J Immunol; 1990 Feb; 144(4):1382-6. PubMed ID: 2303711
[TBL] [Abstract][Full Text] [Related]
24. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo.
Drebin JA; Link VC; Greene MI
Oncogene; 1988 Apr; 2(4):387-94. PubMed ID: 2896329
[TBL] [Abstract][Full Text] [Related]
25. Cytotoxicity of adriamycin-containing immunoliposomes targeted with anti-ganglioside monoclonal antibodies.
Ohta S; Igarashi S; Honda A; Sato S; Hanai N
Anticancer Res; 1993; 13(2):331-6. PubMed ID: 8517645
[TBL] [Abstract][Full Text] [Related]
26. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.
Ragupathi G; Livingston PO; Hood C; Gathuru J; Krown SE; Chapman PB; Wolchok JD; Williams LJ; Oldfield RC; Hwu WJ
Clin Cancer Res; 2003 Nov; 9(14):5214-20. PubMed ID: 14614001
[TBL] [Abstract][Full Text] [Related]
27. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
Pastorino F; Brignole C; Marimpietri D; Di Paolo D; Zancolli M; Pagnan G; Ponzoni M
Ann N Y Acad Sci; 2004 Dec; 1028():90-103. PubMed ID: 15650235
[TBL] [Abstract][Full Text] [Related]
28. Human monoclonal antibody against ganglioside GD2: use in development of enzyme-linked immunosorbent assay for the monitoring of anti-GD2 in cancer patients.
Tai T; Cahan LD; Paulson JC; Saxton RE; Irie RF
J Natl Cancer Inst; 1984 Sep; 73(3):627-33. PubMed ID: 6206271
[TBL] [Abstract][Full Text] [Related]
29. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells.
Cheung NK; Saarinen UM; Neely JE; Landmeier B; Donovan D; Coccia PF
Cancer Res; 1985 Jun; 45(6):2642-9. PubMed ID: 2580625
[TBL] [Abstract][Full Text] [Related]
30. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.
Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN
Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727
[TBL] [Abstract][Full Text] [Related]
31. Isolation and immunochemical characterization of antibodies from the sera of cancer patients which are reactive against human melanoma cell membranes by affinity chromatography.
Gupta RK; Silver HK; Reisfeld RA; Morton DL
Cancer Res; 1979 May; 39(5):1683-95. PubMed ID: 427806
[TBL] [Abstract][Full Text] [Related]
32. Molecular cloning of a human monoclonal antibody reactive to ganglioside GM3 antigen on human cancers.
Hoon DS; Wang Y; Sze L; Kanda H; Watanabe T; Morrison SL; Morton DL; Irie RF
Cancer Res; 1993 Nov; 53(21):5244-50. PubMed ID: 7916649
[TBL] [Abstract][Full Text] [Related]
33. Mouse monoclonal antibody to a melanoma-carcinoma-associated antigen synthesized by a human melanoma cell line propagated in serum-free medium.
Chee DO; Yonemoto RH; Leong SP; Richards GF; Smith VR; Klotz JL; Goto RM; Gascon RL; Drushella MM
Cancer Res; 1982 Aug; 42(8):3142-7. PubMed ID: 7046918
[TBL] [Abstract][Full Text] [Related]
34. Cell binding and tumor inhibiting functions of a new antihuman melanoma murine monoclonal antibody.
Abdel-Wahab Z; Darrow T; Vervaert CE; Crowley NJ; Seigler HF
Mol Biother; 1991 Sep; 3(3):163-9. PubMed ID: 1768367
[TBL] [Abstract][Full Text] [Related]
35. Distribution of disialoganglioside GD2-antigen and binding of anti-GD2 antibodies on spheroids of neuroblastoma cell line.
Heiss P; Bermatz S; Wehnes H; Heinzmann U; Senekowitsch-Schmidtke R
Anticancer Res; 1997; 17(4B):3145-7. PubMed ID: 9329622
[TBL] [Abstract][Full Text] [Related]
36. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).
Hank JA; Surfus JE; Gan J; Jaeger P; Gillies SD; Reisfeld RA; Sondel PM
Clin Cancer Res; 1996 Dec; 2(12):1951-9. PubMed ID: 9816154
[TBL] [Abstract][Full Text] [Related]
37. Incorporation, remodeling and re-expression of exogenous gangliosides in human cancer cell lines in vitro and in vivo.
Nishio M; Furukawa K
Nagoya J Med Sci; 2004 May; 67(1-2):35-44. PubMed ID: 15279066
[TBL] [Abstract][Full Text] [Related]
38. Light chain variants of an IgG3 anti-GD3 monoclonal antibody and the relationship among avidity, effector functions, tumor targeting, and antitumor activity.
Chapman PB; Lonberg M; Houghton AN
Cancer Res; 1990 Mar; 50(5):1503-9. PubMed ID: 2105840
[TBL] [Abstract][Full Text] [Related]
39. Selection of novel peptide mimics of the GD2 ganglioside from a constrained phage-displayed peptide library.
Horwacik I; Czaplicki D; Talarek K; Kowalczyk A; Bolesta E; Kozbor D; Rokita H
Int J Mol Med; 2007 May; 19(5):829-39. PubMed ID: 17390090
[TBL] [Abstract][Full Text] [Related]
40. Recombinant human hexamer-dominant IgM monoclonal antibody to ganglioside GM3 for treatment of melanoma.
Azuma Y; Ishikawa Y; Kawai S; Tsunenari T; Tsunoda H; Igawa T; Iida S; Nanami M; Suzuki M; Irie RF; Tsuchiya M; Yamada-Okabe H
Clin Cancer Res; 2007 May; 13(9):2745-50. PubMed ID: 17473208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
